Altered plasma glutamate and glutamine levels in patients with drug-resistant and drug-responsive symptomatic focal epilepsy

Neurosciences (Riyadh). 2021 Oct;26(4):315-322. doi: 10.17712/nsj.2021.4.20210041.

Abstract

Objectives: To compare the levels of plasma glutamate and glutamine in drug-resistant or drug-responsive symptomatic focal epilepsy. Dysfunctional glutamate neurotransmission plays an essential role in epilepsy pathophysiology.

Methods: This cross-sectional study included 80 drug-resistant and 42 drug-responsive symptomatic focal epileptic patients and 132 healthy controls from June 2017 to February 2018. Plasma glutamate and glutamine levels were assessed via high-performance liquid chromatography.

Results: Patients with drug-resistant symptomatic focal epilepsy had significantly higher plasma glutamate levels than healthy controls, whereas those with the drug-responsive disease had higher plasma glutamine levels than healthy controls. These results indicate that plasma glutamate and glutamine levels can discriminate patients with drug-resistant and drug-responsive symptomatic focal epilepsy from control individuals with the areas under the curve values of 0.931 and 0.72, respectively.

Conclusion: Elevated plasma glutamate levels are associated with drug-resistant symptomatic focal epilepsy and may aid the diagnosis of drug-resistant symptomatic focal epilepsy.

MeSH terms

  • Cross-Sectional Studies
  • Epilepsies, Partial* / drug therapy
  • Glutamic Acid
  • Glutamine
  • Humans
  • Pharmaceutical Preparations*

Substances

  • Pharmaceutical Preparations
  • Glutamine
  • Glutamic Acid